CryoPort (NASDAQ:CYRX) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded CryoPort from a "sell" to a "hold"; the stock carries a consensus analyst rating of Moderate Buy (seven Buy, one Hold, one Sell) with a $13.31 consensus target price.
• In the latest quarter CryoPort reported EPS of ($0.21), missing estimates by $0.02, while revenue beat at $45.45 million; the stock was trading around $10.59 (up ~4.1%) after the report.
• Insiders have sold about 59,939 shares (~$471k) in the past 90 days, including a CFO sale, while institutional ownership is high at roughly 92.9% and several hedge funds have recently increased stakes.

CryoPort (NASDAQ:CYRX - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

Several other analysts have also recently weighed in on the company. Needham & Company LLC lifted their price target on CryoPort from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, March 4th. Weiss Ratings reissued a "sell (d+)" rating on shares of CryoPort in a report on Friday, March 27th. Finally, Craig Hallum assumed coverage on CryoPort in a report on Monday, March 30th. They set a "buy" rating and a $15.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, CryoPort currently has an average rating of "Moderate Buy" and a consensus target price of $13.31.

CryoPort Stock Up 4.1%

CYRX opened at $10.59 on Friday. The stock has a market cap of $531.62 million, a price-to-earnings ratio of 8.02 and a beta of 1.68. The business has a 50 day moving average of $8.79 and a 200-day moving average of $9.31. CryoPort has a 12-month low of $5.31 and a 12-month high of $11.45.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $45.45 million for the quarter, compared to analyst estimates of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. As a group, analysts expect that CryoPort will post -0.73 earnings per share for the current year.

Insiders Place Their Bets

In other CryoPort news, CFO Robert Stefanovich sold 38,700 shares of the firm's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $7.76, for a total transaction of $300,312.00. Following the transaction, the chief financial officer owned 255,701 shares in the company, valued at $1,984,239.76. This trade represents a 13.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark W. Sawicki sold 3,235 shares of the firm's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $25,880.00. Following the transaction, the insider owned 103,697 shares in the company, valued at approximately $829,576. This trade represents a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 59,939 shares of company stock worth $471,183 in the last 90 days. Company insiders own 10.00% of the company's stock.

Hedge Funds Weigh In On CryoPort

A number of hedge funds have recently added to or reduced their stakes in CYRX. Mak Capital One LLC bought a new position in CryoPort during the 3rd quarter worth $7,756,000. UBS Group AG increased its stake in shares of CryoPort by 112.7% in the 3rd quarter. UBS Group AG now owns 1,331,521 shares of the company's stock valued at $12,623,000 after purchasing an additional 705,649 shares during the last quarter. Millennium Management LLC increased its stake in shares of CryoPort by 23.8% in the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company's stock valued at $31,150,000 after purchasing an additional 623,896 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of CryoPort by 283.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company's stock valued at $4,970,000 after purchasing an additional 387,440 shares during the last quarter. Finally, First Eagle Investment Management LLC bought a new position in shares of CryoPort in the 4th quarter valued at $2,996,000. Institutional investors own 92.90% of the company's stock.

About CryoPort

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.